NCT05994677

Brief Summary

The study is to assess frequency of NASH in Psoriatic patient and to measure the level of proinflammatory cytokines including TNFα, interleukin (IL)-6 and IL-17 and anti-inflammatory cytokines including IL10, IL35 by ELISA.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
59

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2023

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2023

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

August 9, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 16, 2023

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2024

Completed
Last Updated

August 16, 2023

Status Verified

August 1, 2023

Enrollment Period

1 year

First QC Date

August 9, 2023

Last Update Submit

August 15, 2023

Conditions

Nash

Keywords

NASHPsoriasis

Outcome Measures

Primary Outcomes (1)

  • Main

    To find out if there is a shared inflammatory network between psoriasis and Non Alcoholic Steatohepatitis or not.

    Baseline

Secondary Outcomes (1)

  • subsidiary

    Baseline

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Psoriatic patients above 18 years not diabetic and not receiving treatment for psoriasis.

You may qualify if:

  • Any naive psoriatic patient above 18 years old.

You may not qualify if:

  • Any psoriatic patient who received treatment for psoriasis.
  • Diabetic patients.
  • Patients under 18 years old.
  • Patient's refusal.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Non-alcoholic Fatty Liver DiseasePsoriasis

Condition Hierarchy (Ancestors)

Fatty LiverLiver DiseasesDigestive System DiseasesSkin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident doctor

Study Record Dates

First Submitted

August 9, 2023

First Posted

August 16, 2023

Study Start

August 1, 2023

Primary Completion

August 1, 2024

Study Completion

August 1, 2024

Last Updated

August 16, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share